Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

12.31 +0.26 (+2.16%)
Streaming Delayed Price Updated: 10:26 AM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Cathie Wood Bets Big On Roblox With $19.5M Purchase — Also Loads Up On This Biotech Stock
 
Via Benzinga
5 Penny Stocks With Explosive 5X Potential
Penny stocks are inherently risky, but investing in low-priced companies with wide "moats" can shift the odds in investors' favor. 
Via InvestorPlace
3 Growth Stocks to Buy for 100% Returns
These three growth stocks to buy could provide triple-digit percentage returns for investors in the near to mid term. 
Via InvestorPlace
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
 
Via Benzinga
This Growth Stock Is Down 63% in 1 Year. Here's Why You Should Buy the Dip and Hold It for 5 Years
The bear market hasn't been kind, but the future could be a lot better. 
Via The Motley Fool
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Ginkgo Bioworks Holdings's Earnings: A Preview
 
Via Benzinga
Is It Too Early to Invest in Ginkgo Bioworks?
Ginkgo is on track to easily beat its guidance for 2022. But what about its bottom line? 
Via The Motley Fool
Bragar Eagel & Squire is Investigating Certain Officers and Directors of C3.ai, Ginkgo Bioworks, and Polished on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ginkgo Bioworks Holdings, Inc. - DNA
From Kahn Swick & Foti, LLC
Via Business Wire
Luminar Technologies, EHang Holdings And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
7 Penny Stocks With Massive Growth Potential
If you laugh at red ink, these tempting ideas just might be for you. 
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Buy the Dip: 2 Exceptional Growth Stocks to Grab Before the Next Bull Market
Now's the time to load up on stocks that got dented in the bear market. 
Via The Motley Fool
GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Cronos Group Reports 2022 Fourth Quarter and Full-Year Results
From Cronos Group Inc.
Via GlobeNewswire
To The Moon: Intuitive Machines Blasts 10x in a Week...But Why?
The modern version of the Cold War Space Race has implications for scientific discovery and satellite communications. Intuitive Machines is in the thick of it. 
Via MarketBeat
This Biotech Is Already Using AI, but Is the Growth Stock a Buy?
Few biotechs can claim to be using AI in as central of a role as Ginkgo Bioworks. 
Via The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ginkgo Bioworks Holdings Inc. (DNA) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
2 Bruised Growth Stocks to Buy While They're Cheap
Both are on the verge of fast growth, and they haven't had any major setbacks yet. 
Via The Motley Fool
The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
Biotech stocks were hard-hit in 2022, but these disruptive names in the field of synthetic biology can be big winners in 2023. 
Via InvestorPlace
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
These stocks are risky. But they just might deliver huge gains if analysts are right. 
Via The Motley Fool
Investigation Announced for Investors Who Lost Money with NYSE: DNA Shares over Possible Violations of Securities Laws by Ginkgo Bioworks Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 02/01/2023 -- An investigation was announced for investors of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) shares over potential securities laws violations by Ginkgo Bioworks... 
Via SBWire
GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
3 Penny Stocks That Could Rise 500% in 2023
Tilt the odds in your favor in 2023 with some of these high-potential penny stocks. The risks are high, but so are the rewards. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
Three Pharma Stocks to Sell Before They Die
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
Down 76% This Year, Is This Growth Stock Now a Screaming Buy?
The company's strategy will take time to implement, but it'll make investors a lot richer if it works. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.